Komori
Lobtex (5969) · FactSoftened

Recognition of R&D expenses

First written in FY2017-Q1. 18 of 33 entries say "Advanced", first in FY2018. Latest entry: FY2026.

33entries
11years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2017-Q1 – FY2018-Q3AdvancedFY2020-Q3 – FY2022-Q2AdvancedFY2023-Q3 – FY2026-H12016: 220162017: 320172018: 420182019: 420192020: 420202021: 320212022: 420222023: 320232024: 320242025: 220252026: 12026
Same theme, other companies
Decline in R&D ExpenditureA theme 56 companies write about · 51 as a headwind · 4 as a tailwind

Lobtex moved to the "Worse" side of this theme in 2026, 1 year after the typical company in this theme (2025).

1 other company's latest entry also says "Softened".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 56 companies compared. The sentences above are computed from all 56.
Full recordFilings, disclosures and news, newest first
  1. FY2026SoftenedAnnual report

    「Total research and development expenses for the current consolidated fiscal year amounted to ¥130 million.」

    Full-year research and development expenses decreased from ¥145 million in the previous fiscal year to ¥130 million.
  2. FY2026-H1AdvancedAnnual report

    「Total research and development expenses for the current interim consolidated accounting period amounted to ¥65 million.」

    Research and development expenses increased from ¥55 million in the same period of the previous year to ¥65 million.
  3. FY2025AdvancedAnnual report

    「Total research and development expenses incurred by the Group during the current consolidated fiscal year amounted to ¥145 million.」

    Full-year research and development expenses increased from ¥135 million in the previous fiscal year to ¥145 million.
  4. FY2025-H1AdvancedAnnual report

    「Total research and development expenses for the current interim consolidated accounting period amounted to ¥55 million.」

    Research and development expenses increased from ¥50 million in the same period of the previous year to ¥55 million.
  5. FY2024AdvancedAnnual report

    「Total research and development expenses incurred by the Group during the current consolidated fiscal year amounted to ¥135 million.」

    Full-year research and development expenses amounted to ¥135 million, up from ¥122 million in the previous fiscal year.
  6. FY2024-Q3AdvancedAnnual report

    「Total research and development expenses for the third quarter of the current consolidated cumulative period amounted to ¥103 million.」

    The total research and development expenses for the third quarter cumulative period were disclosed as ¥103 million.
  7. FY2024-Q2AdvancedAnnual report

    「Total research and development expenses for the second quarter of the current consolidated cumulative period amounted to ¥62 million.」

    Research and development expenses increased from ¥50 million in the same period of the previous year to ¥62 million.
  8. FY2024-Q1AdvancedAnnual report

    「Total research and development expenses for the first quarter of the current consolidated cumulative period amounted to ¥29 million.」

    Research and development expenses increased from ¥28 million in the same period of the previous year to ¥29 million.
  9. FY2023-Q3AdvancedAnnual report

    「Total research and development expenses for the third quarter of the current consolidated cumulative period amounted to ¥81 million.」

    Research and development expenses increased from ¥79 million in the same period of the previous year to ¥81 million.
  10. FY2023-Q2SoftenedAnnual report

    「Total research and development expenses for the second quarter of the current consolidated cumulative period amounted to ¥50 million.」

    Research and development expenses decreased from ¥62 million in the same period of the previous year to ¥50 million.
  11. FY2023-Q1SoftenedAnnual report

    「Total research and development expenses for the first quarter of the current consolidated cumulative period amounted to ¥21 million.」

    Research and development expenses decreased from ¥28 million in the same period of the previous year to ¥21 million.
  12. FY2022SoftenedAnnual report

    「Total research and development expenses incurred by the Group during the current consolidated fiscal year amounted to ¥122 million.」

    Full-year research and development expenses amounted to ¥122 million, down from ¥128.75 million in the previous fiscal year.
  13. FY2022-Q3SoftenedAnnual report

    「Total research and development expenses for the third quarter of the current consolidated cumulative period amounted to ¥94 million.」

    Research and development expenses decreased from ¥100 million in the same period of the previous year to ¥94 million.
  14. FY2022-Q2AdvancedAnnual report

    「Total research and development expenses for the second quarter of the current consolidated cumulative period amounted to ¥62 million.」

    Research and development expenses increased from ¥50 million in the same period of the previous year to ¥62 million.
  15. FY2022-Q1AdvancedAnnual report

    「Total research and development expenses for the first quarter of the current consolidated cumulative period amounted to ¥28 million.」

    Research and development expenses increased from ¥26 million in the same period of the previous year to ¥28 million.
  16. FY2021-Q3AdvancedAnnual report

    「Research and development expenses totaled ¥100 million for the cumulative third quarter of the current consolidated fiscal year.」

    Research and development expenses increased from ¥88 million in the same period of the previous year to ¥100 million.
  17. FY2021-Q2AdvancedAnnual report

    「Total research and development expenses for the second quarter of the current consolidated cumulative period amounted to ¥60 million.」

    Research and development expenses increased from ¥50 million in the same period of the previous year to ¥60 million.
  18. FY2021-Q1AdvancedAnnual report

    「Total research and development expenses for the first quarter of the current consolidated cumulative period amounted to ¥30 million.」

    Research and development expenses increased from ¥26 million in the same period of the previous year to ¥30 million.
  19. FY2020AdvancedAnnual report

    「Total research and development expenses incurred by the Group during the current consolidated fiscal year amounted to ¥130 million.」

    Research and development expenses increased from ¥108 million in the previous fiscal year to ¥130 million.
  20. FY2020-Q3AdvancedAnnual report

    「Total research and development expenses for the third quarter of the current consolidated cumulative period amounted to ¥88 million.」

    Research and development expenses increased from ¥83 million in the same period of the previous year to ¥88 million.
  21. FY2020-Q2RestatedAnnual report

    「Total research and development expenses for the second quarter of the current consolidated cumulative period amounted to ¥50 million.」

    The Company has continued to recognise and disclose research and development expenses. The amount was also ¥50 million in the same period of the previous year.
  22. FY2020-Q1AdvancedAnnual report

    「Total research and development expenses for the first quarter of the current consolidated cumulative period amounted to ¥26 million.」

    The Company has continued to recognise and disclose research and development expenses, which increased from ¥22 million in the same period of the previous year to ¥26 million.
  23. FY2019AdvancedAnnual report

    「Total research and development expenses incurred by the Group during the current consolidated fiscal year amounted to ¥108 million.」

    Research and development expenses were finalised at ¥108 million for the full year, up from ¥79 million for the third quarter cumulative period.
  24. FY2019-Q3RestatedAnnual report

    「Total research and development expenses for the third quarter of the current consolidated cumulative period amounted to ¥79 million.」

    The Company has continued to recognise and disclose research and development expenses.
  25. FY2019-Q2RestatedAnnual report

    「Total research and development expenses for the second quarter of the current consolidated cumulative period amounted to ¥50 million.」

    The Company has continued to recognise and disclose research and development expenses.
  26. FY2019-Q1RestatedAnnual report

    「Total research and development expenses for the first quarter of the current consolidated cumulative period amounted to ¥22 million.」

    The Company has continued to recognise and disclose research and development expenses.
  27. FY2018AdvancedAnnual report

    「Total research and development expenses incurred by the Group during the current consolidated fiscal year amounted to ¥112 million.」

    Full-year research and development expenses amounted to ¥112 million, an increase from ¥83 million in the third quarter cumulative period.
  28. FY2018-Q3RestatedAnnual report

    「Total research and development expenses for the third quarter of the current consolidated cumulative period amounted to ¥83 million.」

    The Company has continued to recognise and disclose research and development expenses.
  29. FY2018-Q2RestatedAnnual report

    「Total research and development expenses for the second quarter of the current consolidated cumulative period amounted to ¥54 million.」

    The Company has continued to recognise and disclose research and development expenses.
  30. FY2018-Q1RestatedAnnual report

    「Total research and development expenses for the first quarter of the current consolidated cumulative period amounted to ¥28 million.」

    The Company has continued to recognise and disclose research and development expenses.
  31. FY2017-Q3RestatedAnnual report

    「Total research and development expenses for the third quarter of the current consolidated cumulative period amounted to ¥73 million.」

    The total research and development expenses for the third quarter cumulative period were disclosed.
  32. FY2017-Q2RestatedAnnual report

    「Total research and development expenses for the second quarter of the current consolidated cumulative period amounted to ¥47 million.」

    The company disclosed total research and development expenses of ¥73 million for the first six months of the current consolidated fiscal year.
  33. FY2017-Q1First statedAnnual report

    「Total research and development expenses for the first quarter of the current consolidated cumulative period amounted to ¥26 million.」

    The total research and development expenses for the cumulative quarter were disclosed.
Moved together

"Decrease in Cash Flow from Operating Activities" moved the same way as this thread, in the same document, in 9 of its 33 moves.

987776★123456
  1. ★This thread
  2. 1Decrease in Cash Flow from Operating Activities9×
  3. 2Increase in Net Assets Due to Growth in Retained Earnings8×
  4. 3Expanding sales through the launch and continued sale of new and newly planned products7×
  5. 4Launch of new higher-functionality hand tools, drills, cable tools and other products7×
  6. 5Strengthening organized sales activities through the establishment of the Sales Planning Department7×
  7. 6Higher revenue and higher profit in the Leisure and Other Business6×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
Lobtex's next results are scheduled for 2026-11-10. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.